Consumo y costo de antidiabéticos orales y antihipertensivos, en pacientes del Centro de Salud de Liberación Social, Julio 2021-Abril 2022.
No Thumbnail Available
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
El presente informe tuvo como objetivo determinar el consumo de antidiabéticos orales y antihipertensivos, en pacientes del centro de salud de Liberación Social, Julio 2021-Abril 2022.con el fin de contribuir al uso racional y eficiente de estos medicamentos. Los datos de antihipertensivos y antidiabéticos comúnmente usados fueron obtenidos de los registros diarios medicamentos contenidos en la base de datos del sistema de ventas del centro de salud. Luego fueron procesados en una hoja de cálculo del programa Microsoft Excel 2013, se utilizó el consumo y costo mensual de antihipertensivos y antidiabéticos con lo que se evidencio los siguientes resultados; el consumo mensual y tendencia promedio expresado en número de unidades dispensadas de losartán, enalapril y captorpil fue 754, 784 y 678 respectivamente; metformina y glibenclamida fue 769 y 683 en pacientes del centro de salud de Liberación Social; presentó el mayor y menor consumo en el mes de enero y octubre para antihipertensivos. EL mayor consumo en el mes de febrero y el menor consumo en el mes de setiembre para antidiabéticos. El costo mensual promedio de expresado en nuevos soles de losartan, enalapril y captopril fue de S/.30.18, S/.23.50y S/.22.89 respectivamente; metformina y glibenclamida fue de S/.46.11 y S/.20.50 en pacientes del centro de salud de liberación social; presentó el mayor consumo en el mes de enero ambos grupos y el menor consumo en el mes de octubre y setiembre respectivamente.
ABSTRACT The objective of this report was to determine the consumption of oral antidiabetic and antihypertensive drugs, in patients of the social liberation health center, from July 2021- April 2022, in order to contribute to the rational and efficient use of these medications. The data on antihypertensive and antidiabetic drugs used were obtained from the daily medication records contained in the database of the health center's sales system. Then they were processed in a spreadsheet of the Microsoft Excel 2013 program, the consumption and monthly cost of antihypertensive and antidiabetic drugs were obtained, which showed the following results; the average monthly consumption and trend increased in number of units dispensed of losartan, enalapril and captorpil was 754, 784 and 678 respectively; metformin and glibenclamide were 769 and 683, in patients from the social liberation health center; presented the highest and lowest consumption in the month of January and October for antihypertensives. The highest consumption in the month of February and the lowest consumption in the month of September for antidiabetics. The average monthly cost of increase in nuevos soles for losartan, enalapril and captopril was S/.30.18, S/.23.50 and S/.22.89, respectively; metformin and glibenclamide was S/.46.11 and S/.20.50, in patients from the social liberation health center; presented the highest consumption in the month of January for both groups and the lowest consumption in the month of October and September respectively.
ABSTRACT The objective of this report was to determine the consumption of oral antidiabetic and antihypertensive drugs, in patients of the social liberation health center, from July 2021- April 2022, in order to contribute to the rational and efficient use of these medications. The data on antihypertensive and antidiabetic drugs used were obtained from the daily medication records contained in the database of the health center's sales system. Then they were processed in a spreadsheet of the Microsoft Excel 2013 program, the consumption and monthly cost of antihypertensive and antidiabetic drugs were obtained, which showed the following results; the average monthly consumption and trend increased in number of units dispensed of losartan, enalapril and captorpil was 754, 784 and 678 respectively; metformin and glibenclamide were 769 and 683, in patients from the social liberation health center; presented the highest and lowest consumption in the month of January and October for antihypertensives. The highest consumption in the month of February and the lowest consumption in the month of September for antidiabetics. The average monthly cost of increase in nuevos soles for losartan, enalapril and captopril was S/.30.18, S/.23.50 and S/.22.89, respectively; metformin and glibenclamide was S/.46.11 and S/.20.50, in patients from the social liberation health center; presented the highest consumption in the month of January for both groups and the lowest consumption in the month of October and September respectively.
Description
Keywords
Antihipertensivos, Antidiabéticos, Consumo, Costo